Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGER | Q15109 | 3/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 3/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.42 |
| ▸ | ITK | Q08881 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.39 |
| ▸ | PYGL | P06737 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL96038 | 0.81 | HSD11B1 (0.62) | AGERMTNR1AHSD11B1MEN1KMT2A | |
| SCHEMBL95632 | 0.76 | AGER (0.76) | AGERMTNR1AMEN1KMT2ASLC6A9 | |
| SCHEMBL95169 | 0.72 | ALDH1A1 (0.58) | MEN1KMT2AKDM4ELMNAALOX15 | |
| SCHEMBL3178423 | 0.71 | ITK (0.43) | F2ITKMEN1KMT2A | |
| SCHEMBL10722280 | 0.71 | HSD11B1 (0.70) | AGERMTNR1AHSD11B1MEN1KMT2A | |
| SCHEMBL4486060 | 0.71 | HSD11B1 (0.61) | AGERMTNR1AHSD11B1MEN1KMT2A | |
| SCHEMBL15492946 | 0.71 | AGER (0.51) | AGERMTNR1AHSD11B1MEN1KMT2A | |
| SCHEMBL5475728 | 0.71 | PYGL (0.39) | AGERF2PYGLALDH1A1 | |
| SCHEMBL14534797 | 0.71 | F2 (0.40) | F2ITKPYGLALDH1A1 | |
| SCHEMBL8773489 | 0.71 | ALDH1A1 (0.39) | AGERMTNR1AF2PYGLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2426128-A1 | Carbostyril compound | Otsuka Pharmaceutical Co., Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | disclosed |
| US-7777038-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-7763562-B2 | Heteroatom bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20090326008-A1 | NF-kappa B Inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| CN-101489555-A | Nf-kappa | OTSUKA PHARMA CO LTD (JP) | 2009-07-22 | — | — | CN | disclosed |
| EP-2043644-A1 | NF- B INHIBITOR | Otsuka Pharmaceutical Co., Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008010601-A1 | NF- ϰB INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | WO | disclosed |
| US-20070179173-A1 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| US-20070135597-A1 | Heteroatom bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-06-14 | — | — | US | disclosed |
| WO-2006065809-A2 | HETEROATOM BRIDGED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326008-A1 | NF-kappa B Inhibitor | NFKBIA, NFKB2, IKBKB | AGER 3852/4885MTNR1A 1110/4885F2 2751/4885 |
| US-20070179173-A1 | Carbostyril compound | GTF2F1, F3, GTF2F2 | AGER 966/4885MTNR1A 460/4885F2 13/4885 |
| US-20070135597-A1 | Heteroatom bridged metallocene compounds for olefin polymerization | AP2M1, AP1M1, PYM1 | AGER 1466/4885MTNR1A 3719/4885F2 143/4885 |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | GTF2F1, F3, GTF2F2 | AGER 966/4885MTNR1A 460/4885F2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.